Bottom line
Is PPH a good fund? The bottom line
PPH is a managed health care sector ETF from VanEck.
Annual fees run 0.36% — about $36 a year on every $10,000 invested, cheaper than 90% of health care sector funds we track.
It returned +21.9% over one year, +11.3% a year over five years, +6.7% a year over ten (as of Dec 31, 2025, per its prospectus).
With $879 million in net assets and 26 holdings, its largest position is Eli Lilly & Co (20.2%) and the top 10 make up 72.7% of the portfolio.
What stands out
- Low cost: cheaper than 90% of health care sector peers
- 5-year return beat 97% of category peers
What to watch
- Concentrated: top 10 holdings are 72.7% of assets
Updated Nov 19, 2026
What PPH invests in
VanEck Pharmaceutical ETF (the Fund) seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the MVIS US Listed Pharmaceutical 25 Index (the Pharmaceutical Index or the Index).
The Fund normally invests at least 80% of its total assets in securities that comprise the Funds benchmark index. For purposes of this policy, the term assets means net assets plus the amount of any borrowings for investment purposes. The Pharmaceutical Index includes common stocks and depositary receipts of U.S. exchange-listed companies in the pharmaceutical industry. Such companies may include medium-capitalization companies and foreign companies that are listed on a U.S. exchange. To be initially eligible for the Pharmaceutical Index, companies must generate at least 50% of their revenues from pharmaceuticals. Pharmaceuticals include companies engaged primarily in research (including research contractors) and development as well as production, marketing and sales of pharmaceuticals (excluding pharmacies). Of the largest 50 stocks in the pharmaceutical industry by full market…
From the fund's prospectus (filed Jan 27, 2026).
PPH performance
| 1 yr | 5 yr | 10 yr | |
|---|---|---|---|
| PPH | +21.9% | +11.3% | +6.7% |
| Health Care Sector median | +14.5% | +4.2% | +7.9% |
Source: Fund prospectus, as of Dec 31, 2025
What PPH costs
On a $10,000 investment, PPH's 0.36% expense ratio costs about $36 a year. The prospectus estimates $456 in total costs over 10 years (assuming 5% annual returns). The median health care sector fund charges 0.96%.
PPH top 10 holdings
| # | Holding | % of fund |
|---|---|---|
| 1 | Eli Lilly & Co | 20.23% |
| 2 | Novartis AG | 10.63% |
| 3 | Merck & Co Inc | 9.85% |
| 4 | Novo Nordisk A/S | 5.37% |
| 5 | AbbVie Inc | 4.57% |
| 6 | Pfizer Inc | 4.51% |
| 7 | Bristol-Myers Squibb Co | 4.47% |
| 8 | Gsk Plc | 4.42% |
| 9 | Johnson & Johnson | 4.35% |
| 10 | AstraZeneca PLC | 4.33% |
Source: SEC Form N-PORT, period ended Jun 30, 2026
The top 10 make up 72.7% of the fund. See all top 25 holdings and asset mix →